By Colin Kellaher
Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic leukemia.
Eli Lilly on Friday said the recommendation covers Jaypirca for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a Bruton's tyrosine kinase inhibitor.
The Indianapolis drugmaker said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the next one to two months.
Eli Lilly previously won conditional European approval for Jaypirca in adults with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 28, 2025 08:59 ET (13:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。